IMV Announces Annual and Special Meeting of Shareholders Voting Results

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Jun 29, 2020 05:05 pm
DARTMOUTH, Nova Scotia -- 

IMV Inc. (“IMV” or the “Company”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company, today announced the voting results from its annual and special meeting of shareholders held on June 29, 2020 (the “Meeting”).

Based on the votes received, all resolutions were accepted including the election of directors, for whom details of the votes are as follows:

Name of nominee

Votes cast FOR

% of votes cast FOR

Votes Withheld

% of votes Withheld

Andrew Sheldon

24,031,180

96.65%

831,947

3.35%

James W. Hall

22,671,885

91.19%

2,191,242

8.81%

Julia P. Gregory

24,738,803

99.50%

124,324

0.50%

Frederic Ors

24,300,178

97.74%

562,950

2.26%

Wayne Pisano

24,454,084

98.35%

409,043

1.65%

Shermaine Tilley

24,738,126

99.50%

125,001

0.50%

Markus Warmuth

24,726,048

99.45%

137,079

0.55%

Shareholders approved the appointment of PricewaterhouseCoopers, LLP, Chartered Professional Accountants, as independent auditor for the Company for the ensuing year and that the board of directors of the Company be authorized to fix its remuneration.

In addition, all amendments to the deferred share unit plan of the Company as described in the management information circular dated May 25, 2020 (the “Circular”) were approved by the shareholders.

Please refer to the Circular available on SEDAR at www.sedar.com for more information on the business transacted at the Meeting. A report on voting results will also be filed on SEDAR.

Departure of Joseph Sullivan Senior Vice President, Business Development

Joseph Sullivan, Senior Vice President, Business Development is leaving IMV to pursue another opportunity. Frederic Ors, Chief Executive Officer commented: ”I want to take this opportunity to thank Joe for his contribution to IMV and wish him the best in his next challenge.”

About IMV

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of cancer-targeted immunotherapies and vaccines based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. IMV is also developing a DPX-based vaccine to fight against COVID-19.

Investor Relations

Marc Jasmin, Senior Director, Investor Relations, IMV
O: (902) 492-1819 ext : 1042
M: (514) 617-9481 E: [email protected]

Josh Rappaport, Director, Stern IR
O: (212) 362-1200
E: [email protected]

Media

Delphine Davan, Director of Communications, IMV
M: (514) 968-1046
E: [email protected]

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).